Etoposide Plus Trastuzumab Shows Benefit in Metastatic BCa Etoposide Plus Trastuzumab Shows Benefit in Metastatic BCa

The median overall survival was 11.3 months in heavily pretreated women with metastatic disease. The study was published as a preprint and has not yet been peer reviewed.First Look
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news